Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.56 |
| ▸ | ACP1 | P24666 | 2/20 | 0.46 |
| ▸ | CDC25B | P30305 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8194669 | 0.82 | PTPN1 (0.59) | PTPN1ACP1CDC25BALDH1A1LMNA | |
| SCHEMBL18610550 | 0.79 | PTPN1 (0.35) | PTPN1PRKCD | |
| SCHEMBL15564116 | 0.78 | PTPN1 (0.50) | PTPN1ACP1CDC25BALDH1A1LMNA | |
| SCHEMBL13403500 | 0.77 | PTPN1 (0.59) | PTPN1ACP1CDC25BALDH1A1LMNA | |
| SCHEMBL14279183 | 0.77 | PTPN1 (0.48) | PTPN1ACP1CDC25BALDH1A1LMNA | |
| SCHEMBL12690929 | 0.77 | PTPN1 (0.51) | PTPN1ACP1CDC25BALDH1A1LMNA | |
| SCHEMBL9730908 | 0.76 | — | — | |
| SCHEMBL5146314 | 0.75 | PTPN1 (0.57) | PTPN1ACP1CDC25BALDH1A1LMNA | |
| SCHEMBL2803500 | 0.73 | PTPN1 (0.46) | PTPN1ACP1CDC25BALDH1A1LMNA | |
| SCHEMBL1670284 | 0.73 | PTPN1 (0.46) | PTPN1ACP1CDC25BALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3882252-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-11693163-B2 | Optical filter and imaging device | AGC Inc. (JP) | 2023-07-04 | — | — | US | disclosed |
| EP-3882252-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| US-11008346-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3154989-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200361962-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | ACTION MEDICAL TECHNOLOGIES, LLC | 2018-11-08 | — | — | US | disclosed |
| US-10093629-B2 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-09 | — | — | US | disclosed |
| US-10053468-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-21 | — | — | US | disclosed |
| US-9926336-B2 | Beta-lactamase inhibitors | VENATORX PHARMACEUTICALS (US) | 2018-03-27 | — | — | US | disclosed |
| US-7323589-B2 | Intermediates for use in retinoid synthesis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2008-01-29 | — | — | US | disclosed |
| US-7323589-B2 | Intermediates for use in retinoid synthesis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2008-01-29 | — | — | US | disclosed |
| US-7323455-B2 | 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators | WYETH (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323455-B2 | 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators | WYETH (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070225281-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7268149-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | WYETH (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268149-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | WYETH (US) | 2007-09-11 | — | — | US | disclosed |
| US-7247625-B2 | 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-07-24 | — | — | US | disclosed |
| US-7192956-B2 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | WYETH (US) | 2007-03-20 | — | — | US | disclosed |
| WO-2004103935-A2 | CYCLIC CARBOTHIOIC ACID DERIVATIVES | FLEXITRAL, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008346-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | PTPN1 3707/4885ACP1 3709/4885CDC25B 1404/4885 |
| US-10053468-B2 | Heterocyclic compound | RORC, RORB, RORA | PTPN1 814/4885ACP1 4681/4885CDC25B 3369/4885 |
| US-10093629-B2 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | RORC, RORB, RORA | PTPN1 655/4885ACP1 3606/4885CDC25B 2486/4885 |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | PTPN1 814/4885ACP1 4681/4885CDC25B 3369/4885 |
| US-20200361962-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | PTPN1 3707/4885ACP1 3709/4885CDC25B 1404/4885 |
| US-20070225281-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | PGR, FSHR, GPR6 | PTPN1 377/4885ACP1 2174/4885CDC25B 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.